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Case Letter
A rare case of herpes zoster ophthalmicus after photodynamic therapy
Madison Bradley a, Sonal Muzumdar BS b, Neda Shahriari MDb, Marti J. Rothe MDb,⇑,
Madina Falcone MD, MS c
a Sacred Heart University, Fairfield, CT, United States
bDepartment of Dermatology, University of Connecticut, Farmington, CT, United States
cDepartment of Ophthalmology, University of Connecticut, Farmington, CT, United States
Dear Editors:
Topical photodynamic therapy (PDT) is frequently used in der-
matology to treat actinic keratoses (AKs) and superficial non-
melanoma skin cancers (Ibbotson et al., 2019). Herein, we
present an extremely rare case of herpes zoster ophthalmicus
(HZO) after PDT.
An 80-year-old male patient with a history of hypertension and
recurrent blood clots underwent PDT for AKs. His scalp and fore-
head were treated with microdermabrasion, incubated with
aminolevulinic acid hydrochloride for 2 hours, and subsequently
treated with blue light for 16 minutes and 40 seconds. The patient
tolerated treatment well. One week after therapy, he developed a
right-sided headache. Five days later, he reported drooping and
tearing of the right eye and a painful, punctate lesion with overly-
ing crust above the right eyebrow. He had not been vaccinated for
shingles, but reported having chickenpox as a child. He presented
to the emergency department and was febrile to 100.8F. He had
diffuse erythema, edema, and vesicles at various stages of healing
on his right forehead, tip of the nose, and right upper eyelid that
stopped sharply at the midline (Fig. 1). The patient was diagnosed
with HZO and prescribed oral valacyclovir 1 g thrice daily. At the
follow-up visits, he was diagnosed with HZO uveitis and started
on prednisolone eye drops six times daily. One month after initial
presentation, he developed diplopia secondary to cranial nerve
(CN) 6 palsy. Three months later, the patient reported significant
improvement in diplopia and complete resolution of the HZO
symptoms.
HZO, which is caused by a reactivation of the varicella zoster
virus in the ophthalmic branch of the trigeminal nerve, is most
commonly seen in elderly and immunocompromised patients
(Schmidgal and Storie, 2020). The reactivation may be triggered
by a number of factors, including illness, stress, and mechanical
injury (Schmidgal and Storie, 2020). HZ of the cranial nerves is
more likely to be associated with trauma than HZ of other body
locations (Schmidgal and Storie, 2020). HZ has only been described
as an adverse effect of PDT twice to date (Manno and Cohen, 2017;
Wolfsen and Ng, 2002). In one case, a man with non-Hodgkin’s
lymphoma developed HZ of the ophthalmic branch of the trigem-
inal nerve after PDT for AKs, but did not display ocular symptoms
or a CN palsy (Manno and Cohen, 2017). In the second case, a
woman who received PDT for mucosal adenocarcinoma developed
HZ of the thoracic wall (Wolfsen and Ng, 2002).
PDT uses light to activate a photosensitizing agent. This causes
the formation of reactive oxygen species that oxidize essential cel-
lular components, leading to apoptosis and cell necrosis. Although
PDT is generally well-tolerated by patients, common complications
include pain and inflammation at the treatment site (Ibbotson
et al., 2019). The patient presented herein developed HZO shortly
after PDT treatment for AKs. Additionally, he developed a CN 6
palsy. CN palsies occur in 7% to 31% of patients with HZO
(Chaker et al., 2014). Although rare, this case highlights that PDT
may trigger HZO. Providers using PDT should be aware of this risk
and counsel patients appropriately. Additionally, vaccination with
the recombinant zoster vaccine is highly effective, preventing HZ in
>90% of cases. For patients with existing risk factors for HZ, such as
advanced age or immunocompromised status, vaccination for HZ
may be prudent prior to treatment with PDT.
For patients with a history of herpes labialis, the PDT protocol
followed at our institution recommends a 10 day course of oral
valacyclovir 500 mg twice daily, beginning 24 hours prior to the
procedure. Our patient did not have a history of herpes simplex
and therefore, was not treated with antiviral prophylaxis. There
is literature that shows that similar anti viral dosing can prevent
herpes zoster in patients with HIV and lymphoma patients
(Barnabas et al., 2016; Sandherr et al., 2015). Perhaps the not infre-
quent use of HSV prophylaxis in PDT regimens is the reason that
additional cases of zoster provoked by PDT have not been reported.
In addition to shingles vaccination, oral antiviral prophylaxis
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Fig. 1. Erythema and crusting of the right forehead that stopped sharply at the
midline.
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